Search

Introduction: Antimicrobial-resistant pathogens present an ongoing threat to human and animal health, with deaths linked to antimicrobial resistance (AMR) predicted to increase annually. While the misuse and overuse of antibiotics in humans undoubtedly contribute to this escalation, antibiotic use in the veterinary field, including companion animals, also plays a contributing role. Pet owners' desire to improve the quality of life of their pets is likely to support antibiotic use in this field. Consequently, there is a need for antibiotic alternatives to treat bacterial infections. This study set out to screen for antimicrobial peptides known as bacteriocins from bacterial isolates of aerobic/ microaerophilic environments of canine sources and determine their potential as antibiotic alternatives against clinically relevant pathogens. Methods: Following a laboratory-based protocol, 22 bacterial isolates were subjected to whole-genome sequencing (WGS), and a total of 14 putative novel bacteriocins were identified from both class I and II bacteriocin classes. One particular bacteriocin, herein named caledonicin, was identified via in silico analysis from a Staphylococcus caledonicus strain and partially purified for further in vitro evaluation. Results: Caledonicin is a 64-amino acid (IAANLGVSSGTAYS MANALNNISNVATA LTIIGTFTGVGTIGSGIA ATILAILKKKGVAAAAAF) novel circular bacteriocin most closely related to enterocin_NKR-5-3B based on core peptide alignment (39.1%), with a molecular weight of 6077.1 Da. Caledonicin exhibits a broad-spectrum of activity against a range of pathogenic bacteria, including methicillinresistant Staphylococcus aureus (MRSA), methicillin-resistant Staphylococcus pseudintermedius (MRSP), and Listeria monocytogenes; and the gut-related bacterium associated with Crohn's disease, Mediterraneibacter gnavus ATCC 29149 (previously Ruminococcus gnavus ATCC 29149). Discussion: This represents the first bacteriocin screening study involving bacteria from canine sources and confirms this is a rich environment for bacteriocin-producing strains. This study also identifies and characterises the first novel bacteriocin from the staphylococcal species, Staphylococcus caledonicus. [ABSTRACT FROM AUTHOR]

How is the performance of an anticoagulant tested? Dosage adjustments for warfarin are made on the basis of the results of measuring the prothrombin time (PT) on the patient's blood. [...]

Alkaline fuel cells enable the use of earth-abundant elements to replace Pt but are hindered by the sluggish kinetics of the hydrogen oxidation reaction (HOR) in alkaline media. Precious metal-free HOR electrocatalysts need to overcome two major challenges: their low intrinsic activity from too strong a hydrogen-binding energy and poor durability due to rapid passivation from metal oxide formation. Here, we designed a Ni-based electrocatalyst with a 2-nm nitrogen-doped carbon shell (Ni@CNx) that serves as a protection layer and significantly enhances HOR kinetics. A Ni@CNx anode, paired with a Co--Mn spinel cathode, exhibited a record peak power density of over 200 mW/cm² in a completely precious metal-free alkaline membrane fuel cell. Ni@CNx exhibited superior durability when compared to a Ni nanoparticle catalyst due to the enhanced oxidation resistance provided by the CNx layer. Density functional theory calculations suggest that graphitic carbon layers on the surface of the Ni nanoparticles lower the H binding energy to Ni, bringing it closer to the previously predicted value for optimal HOR activity, and single Ni atoms anchored to pyridinic or pyrrolic N defects of graphene can serve as the HOR active sites. The strategy described here marks a milestone in electrocatalyst design for low-cost hydrogen fuel cells and other energy technologies with completely precious metal-free electrocatalysts. [ABSTRACT FROM AUTHOR]